CALGB newsletter

[Guest guest]

CALGB is a cooperative group that conducts important studies for blood and

other cancers.

Newsletter:

http://www.calgb.org/Public/publications/calgabs/2010/summer2010.pdf

At least two item will be of interest:

* Report: Galiximab, an anti-CD80 primatized monoclonal antibody, in

relapsed Hodgkin lymphoma: Final results of CALGB 50602

* Response to the Institute of Medicine's Report

A National Cancer Clinical Trials System for the 21st Century:

Reinvigorating the NCI ative Group Program

" The IOM committee voiced strong opinions concerning the current state of

the Cancer ative Group system. In his opening remarks, committee chair

Mendelsohn described the system for conducting cancer clinical trials

in the United States as " approaching a state

of crisis. " Several key reasons for this were articulated, including: 1)

excessive complexity and redundancy in design and initiation of trials; 2)

lack of an adequate system-wide process for prioritizing trials and

selecting those more likely to succeed; and 3) inadequacy of NCI funding and

lack of insurance plan reimbursement for nonexperimental costs of care in

clinical trials.

All the best,

~ Karl

Patients Against Lymphoma

Patients Helping Patients

Non-profit | Independent | Evidence-based

www.lymphomation.org | Current News: http://bit.ly/f2A0T

How to Help: www.lymphomation.org/how-to-help.htm